Phase 2 N=26 Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=169 Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Stage IIIC Cutaneous Melanoma AJCC v7 · Stage IV Cutaneous Melanoma AJCC v6 and v7 · Unresectable Melanoma
Primary: Overall Survival (OS) — 20.4; 20.1 months — p=0.383
Phase 2 N=32 PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Melanoma (Skin)
Primary: Plasma b-FGF Level Response — 34.5 percentage of participants — p=<0.001
Phase 2 N=49 Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
Melanoma (Skin)
Primary: 9-week Progression-free Survival Rate — 0.44 proportion of patients
Phase 3 N=676 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Melanoma · Metastases
Primary: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone — 9.95…
Phase 2 N=31 Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
Advanced Melanoma · Unresectable Melanoma
Primary: Overall Response Rate (ORR) — 10 percentage of patients
Phase 1 N=39 Immunotherapy of Stage III/IV Melanoma Patients
Melanoma
Primary: Change From Baseline in Mean Number of Adverse Events (Serious and Non Serious Events) — 13.40; 18.40; 23.80; 19.60 Number of adverse events
Phase 2 N=158 Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Melanoma · Malignant Melanoma · Melanoma, Experimental
Primary: Clinical Response — 1; 3; 3; 2 Participants
Phase 2 N=24 Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
Melanoma · Skin Cancer · Cancer
Primary: Overall Objective Response (Complete Response or Partial Response) — 2; 2; 15 participants
Phase 2 N=24 Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
Melanoma · Skin Cancer
Primary: Clinical Tumor Regression. — 0; 0; 6; 0 Participants
Phase 2 N=1,009 A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
Melanoma
Primary: the Incidence of Highgrade (CTCAE v4.0 Grade 3 or Higher), Treatment Related,Select Adverse Events. — 16; 0; 30; 0 Number of Participants
Phase 2 N=41 Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
Melanoma (Skin)
Primary: Evaluation of Objective Clinical Response (CR/PR/SD) — 0; 0; 1; 2 participants
Phase 2 N=24 Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
Metastatic Melanoma · Mucosal Melanoma · Stage IV Cutaneous Melanoma AJCC v6 and v7
Primary: Progression-free Survival (PFS) — 139; 94 days
Phase 2 N=30 Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Acral Lentiginous Malignant Melanoma · Recurrent Melanoma · Stage IIIA Melanoma
Primary: Objective Response Rate — 1; 3; 14; 7 participants
Phase 2 N=84 Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Metastatic Melanoma · Recurrent Melanoma · Stage III Cutaneous Melanoma AJCC v7
Primary: Progression-free Survival — 6.9; 2.3 months — p=0.002
Phase 2 N=76 Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
Intraocular Melanoma · Melanoma (Skin)
Primary: Percentage of Participants With Immune-related Adverse Events (irAEs) — 80.0; 72.0; 65.4 Percentage of participants
Phase 2 N=3 Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Melanoma
Primary: Phase I, Number of Participants With SAE and DLT — 0; 0; 1; 0 Participants
Phase 3 N=1,844 An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma
Melanoma
Primary: Recurrence-free Survival (RFS) - All Randomized Participants — NA; NA Months
Phase 2 N=26 A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
Metastatic Melanoma
Primary: Change in Immune-related Overall Response Rate (irORR) — 20 participants
Phase 2 N=39 Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
Metastatic Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Overall Response Rate, Defined Per RECIST 1.1 — 1; 5; 11; 16 Participants
Phase 2 N=52 Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
Melanoma
Primary: Response to Neoadjuvant Therapy by Therapy Arms: Clinical Response Rates (CR + PR + SD) — 4; 7; 14; 11 Participants
Phase 2 N=15 Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Metastatic Melanoma
Primary: Immune Response Rate — 0.29; 0.67 proportion of participants
Phase 2 N=17 Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
Melanoma
Primary: Clinical Responses in Patients With Metastatic Ocular Melanoma — 0; 0; 9; 7 Participants
Phase 2 N=41 VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Ciliary Body and Choroid Melanoma, Medium/Large Size · Extraocular Extension Melanoma · Iris Melanoma
Primary: Objective Response Rate (CR + PR) — 7.5 percentage of participants
Phase 2 N=4 Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
Melanoma · Skin Cancer
Primary: Complete Response Rates for Patients With Metastatic Melanoma — 0; 0; 0; 0 Participants
Phase 2 N=10 Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Unresectable Malignant Neoplasm · Melanoma · Metastatic Melanoma
Primary: Resectability Rate — 8; 2 Participants
Phase 2 N=64 Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8 · Pathologic Stage III Cutaneous Melanoma AJCC v8 · Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
Primary: Pathologic Complete Response Rate (pCR) — 66.7; 13.3; 38.2 percentage of participants
Phase 2 N=25 Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Recurrent Melanoma · Stage IV Melanoma
Primary: Progression-Free Survival at 4 Months — 22.2 percentage of patients
Phase 2 N=39 Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma
Recurrent Melanoma · Stage IIIA Melanoma · Stage IIIB Melanoma
Primary: Number of Subjects With Objective Response(Partial Response and Complete Response) as Measured by RECIST Criteria — 2 participants
Phase 3 N=502 Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
Melanoma
Primary: Overall Survival (OS) — 11.17; 9.07 Months — p=0.0009